Dynamic biochemical screening of pharmaceutical-nutrient competition, chelation hazards, and chronotherapeutic optimization.
Search by generic chemical name or global brand (e.g., Lipitor, Glucophage, Metformin, Omeprazole, CoQ10, Vitamin B12)
Markedly increases the hazard of fatal lactic acidosis through synergistic lactate accumulation.
Furanocoumarins in grapefruit irreversibly inhibit intestinal CYP3A4, dramatically elevating plasma atorvastatin concentrations.
Depletion Mechanism: Competitively antagonizes the calcium-dependent membrane uptake of the intrinsic factor-vitamin B12 complex in the terminal ileum.
Clinical Significance: Long-term therapy (>3-5 years) substantially increases the risk of megaloblastic anemia and progressive, irreversible peripheral neuropathy (tingling, numbness), frequently misattributed to diabetic neuropathy.
Depletion Mechanism: Secondary impairment of cellular folate trapping and reduced intestinal absorption secondary to cobalamin deficiency.
Clinical Significance: Elevates circulating plasma homocysteine, potentially compounding secondary cardiovascular and endothelial risks.
Depletion Mechanism: Inhibits HMG-CoA reductase in the mevalonate pathway, concurrently halting endogenous ubiquinone (CoQ10) biosynthesis alongside cholesterol synthesis.
Clinical Significance: Impairs mitochondrial electron transport chain phosphorylation, a primary driver of statin-associated muscle symptoms (SAMS), myalgia, and generalized fatigue.
Automatically staggers doses based on pharmacokinetics, multivalent chelation hazards, and circadian digestive dynamics to avoid absorption inhibition.